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Abstract: 
 
The effects of combined treatment with a glucocorticoid receptor (GR) antagonist, Org 34850, 
and a selective serotonin reuptake inhibitor (SSRI), fluoxetine, were investigated on pre- and 
post-synaptic aspects of 5-HT neurotransmission.  Rats were treated for 14 days with Org 34850 
(15 mg/kg/day subcutaneously), fluoxetine (10 mg/kg/day intraperitoneally), or a combination of 
both drugs.  [
3
H]-citalopram binding (an index of 5-HT transporter (5-HTT) expression) was 
only slightly affected by Org 34850 alone: decreased in cortex and midbrain and increased in 
hippocampus.  In contrast, chronic fluoxetine markedly decreased 5-HTT levels in all regions.  
Importantly, this decrease was significantly enhanced by combined Org 34850/fluoxetine 
treatment.  There were no changes in the expression of 5-HTT mRNA, suggesting these effects 
were not due to changes in gene transcription.  Expression of tryptophan hydroxylase mRNA and 
both 5-HT1A autoreceptor mRNA and protein (assessed using [
3
H]-8-OH-DPAT binding) were 
unchanged by any treatment.  The expression of postsynaptic 5-HT1A receptor protein in the 
forebrain was unaltered by fluoxetine, Org 34850 or the combined Org 34850/fluoxetine 
treatment.  Thus, down-regulation of 5-HTT by fluoxetine and its enhancement by Org 34850 
can explain our recent observation that GR antagonists augment the SSRI-induced increase in 
extracellular 5-HT.  In addition, these data suggest that the augmentation of forebrain 5-HT does 
not result in down-regulation of forebrain 5-HT1A receptor expression.  Given the importance of 
5-HT1A receptor-mediated transmission in the forebrain to the antidepressant response, these data 
indicate that co-administration of GR antagonists may be effective in augmenting the 
antidepressant response to SSRI treatment. 
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Introduction 
 
Selective serotonin reuptake inhibitors (SSRIs) are widely used for the treatment of depression.  
Whilst effective in some patients, SSRI treatment does not always induce complete remission of 
depression and many patients have persistent symptoms despite apparently ‘adequate’ dosing 
(Boulenger 2004).  Interestingly, the hypothalamo-pituitary-adrenal (HPA) axis has been shown 
in several recent studies to have an influence on patients’ response to antidepressant treatment.  
Thus, Young et al., (Young, et al 2004) reported that the therapeutic response to SSRIs was 
lower in patients with HPA axis abnormalities than in those with normal HPA axis function. In a 
more recent and larger scale study, Brouwer and colleagues showed that hyperactivity of the 
HPA axis predicted poor treatment response (Brouwer, et al 2006).  Conversely, it has been 
reported that the clinical efficacy of ‘serotonergic’ antidepressants (including SSRIs) is improved 
by co-administration of an inhibitor of glucocorticoid synthesis (Jahn, et al 2004). 
 
The molecular target of SSRI antidepressants is the 5-HT transporter (5-HTT), which they block 
competitively, preventing the reuptake of released 5-HT.  In experimental animals, chronic 
administration of SSRIs has been shown to cause an elevation in extracellular 5-HT in the 
forebrain (Bosker, et al 1995; Dawson, et al 2000).  It is believed that the therapeutic efficacy of 
SSRIs is dependent upon this elevation of forebrain 5-HT.  This contention is supported by data 
showing that acute depletion of tryptophan (the precursor of 5-HT) results in a rapid return of 
symptoms in euthymic patients treated for depression with SSRIs (Delgado, et al 1999).  An 
elevation of forebrain 5-HT levels would, of course, be predicted to increase the activation of 
postsynaptic 5-HT receptors.  Although the particular receptor subtypes involved in the 
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antidepressant response have not been definitively identified, the 5-HT1A receptor is thought to 
have an important role to play (Cowen 2000; Celada, et al 2004). 
 
Since the clinical antidepressant response to SSRIs appears to be both reliant on forebrain 5-HT 
and influenced by corticosteroids, we proposed that glucocorticoids may modulate the ability of 
SSRIs to elevate forebrain 5-HT.  In line with this hypothesis, we found that flattening the 
diurnal corticosterone rhythm in rats attenuates the ability of a chronic SSRI to elevate cortical 5-
HT (Gartside et al., 2003).  Importantly, recently we showed that blockade of glucocorticoid 
receptors (GRs) has the opposite effect, enhancing the ability of an SSRI to elevate forebrain 5-
HT levels (Johnson et al., 2007).  The mechanism underlying the interaction between SSRIs and 
glucocorticoid signalling remains unknown.  However, it is of note that 5-HT neurones in the 
dorsal and median raphe nuclei (DRN and MRN, respectively) express GRs (Harfstrand, et al 
1986; Gartside 2007) which are intracellular transcription regulatory proteins.  Thus, it is 
possible that alterations in glucocorticoid signalling lead to changes in levels of expression of 
particular proteins within 5-HT neurones which ultimately influence extracellular 5-HT. 
 
In the present study we investigated the molecular basis of the SSRI/GR antagonist interaction.  
To this end, we examined the effects of chronic treatment with an SSRI (fluoxetine) and/or a GR 
antagonist (Org 34850) on the expression of 5-HTT in the raphe and various forebrain regions 
considered important in the pathophysiology of depression.  We also examined the expression in 
the raphe of mRNAs which code for the 5-HTT, the 5-HT synthesis enzyme tryptophan 
hydroxylase (TPH), and the 5-HT1A autoreceptor, as well as levels of 5-HT1A autoreceptor 
SE Gartside 
6 
protein.  Finally, in order to examine the consequences of the previously reported changes in 5-
HT levels, we determined expression of postsynaptic 5-HT1A receptors in the forebrain.  
 
Materials and methods 
 
Animals 
Male Hooded Lister rats (150-180g) were purchased from Charles River, UK.  They were housed 
in groups of three in standard caging under controlled conditions of light (lights on 07:00, lights 
off 19:00) and humidity.  Animals were allowed free access to standard rat chow (SDS, UK) and 
tap water, and allowed to acclimatize to the holding facility for at least 5 days before initiating 
treatment.  All experiments were carried out under the Animals (Scientific Procedures) Act 1986 
in accordance with the ‘Guide for the Care and Use of Laboratory Animals’ promulgated by the 
National Institutes of Health.  Animals were healthy throughout and treatment groups did not 
differ in weight at start or end of treatment. 
 
Drug treatments 
Treatments were for 14 days using a 2 x 2 factorial design.  Animals received Org 34850 (15 
mg/kg, s.c.) or its vehicle (30% dimethylsuphoxide: 70% polyethylene glycol) twice daily at 
approximately 07:00 and 18:00.  Concurrently animals also received fluoxetine (10 mg/kg i.p.) 
or its vehicle (sterile water) once daily at approximately 07:00.  This gave four treatment groups: 
vehicle/vehicle, Org/vehicle, vehicle/fluoxetine, and Org/fluoxetine.  
 
Brain sections 
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On the fifteenth day between 8:00-8:30 h, animals were rapidly decapitated.  The brain was 
removed and snap-frozen on dry ice and stored at -80 °C.  Coronal sections (12 μm) were cut on 
a cryostat, thaw mounted onto gelatinised slides, and stored at -80 °C.  Sections were collected 
from the following brain regions (anteroposterior distance from bregma according to Paxinos and 
Watson, 1986):- midbrain (-8.0 to -7.6 mm), ventral hippocampus (-6.04 to -4.8 mm), dorsal 
hippocampus (-3.8 to -3.14 mm), and prefrontal cortex (PFC) (+2.2 to +3.2mm). 
 
In situ hybridization histochemistry 
In situ hybridization histochemistry with oligonucleotide probes was used to determine levels of 
expression of mRNAs encoding 5-HTT, 5-HT1A receptor and TPH in the DRN and MRN.  
Briefly, the sections were fixed and pre-treated for in situ hybridization in a single batch using an 
established protocol (McQuade, et al 2004).  Oligonucleotide probe sequences complimentary to 
bases 1345-1371 of rat 5-HTT mRNA (M79450) (5’ AGC-TTC GTC TCT GGC TTC GTC ATC 
TTC 3’) 1863-1894 of rat TPH2 mRNA (NM 173839.2) (5' CTC ACA CAA TTC CAG CTG 
CTG AGT CCT TGA CC 3') and bases 2105-2151 of rat 5 HT1A receptor mRNA (AF 217200) 
(5’ GGT TAG CGT GGG AGG AAG GGA GAC TAG CTG TCT GAG CGA CAT ACA AG 
3’) (manufactured by MWG-Biotech AG) were used.  Probes were 3′-tail labelled using [
35
S] 
dATP (Perkin Elmer, USA) with terminal deoxynucleotide transferase (Roche).  The labelled 
oligonucleotide probe was added to each section in hybridization buffer (50 % formamide, 4 x 
standard saline citrate (SSC), 10 % dextran sulphate, 5 х Denhardts, 200 μg/ml salmon sperm 
DNA, 100 mg/ml polyA, 25 mM sodium phosphate, 1 mM sodium pyrophosphate and 5 % 
dithiothreitol (Pei, et al 1995).  The sections were incubated overnight (at 38 ºC (5-HTT), 30 ºC 
(TPH2) and 27 ºC (5-HT1A)) in sealed boxes containing 50 % formamide in 4 х SSC.  Sections 
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were then washed three times (20 min) in 1 x SSC at 58 ºC and twice (60 min) at room 
temperature.  After air drying, the sections, together with [
14
C] microscale
TM
 calibration strips 
(Amersham), were exposed to Biomax Hyperfilm
TM
 (Amersham) for (2-12 weeks) before 
automatic development using an Agfa curix compact plus daylight processor
TM
. 
 
Binding Studies 
Citalopram binding was adapted from established protocols (Romero, et al 1998; Hebert, et al 
2001). The slides were pre-incubated in Tris Buffer pH 7.4 (Tris-HCl, 50 mM, NaCl 120 mM, 
KCl 5 mM) at room temperature for 30 min. Slides were then incubated for 2 h at room 
temperature in Tris buffer containing 1.5 nM [
3
H]-citalopram (Amersham; specific activity 84 
Ci/mmol). To determine non-specific binding, two slides from each area were incubated in 1.5 
nM [
3
H]-citalopram together with 20 µM fluoxetine. Following incubation the slides underwent 
two 15 min washes in ice cold Tris buffer, briefly washed in distilled H2O, and left to air dry.   
 
The method used for determining 5-HT1A binding was adapted from that used previously in this 
laboratory and the concentration of ligand ([
3
H]-8-OH-DPAT) necessary for estimation of Bmax 
was determined from full saturation curves (Dr Claire Troakes, pers. comm.).  Slides were pre-
incubated for 30 min at room temperature in Tris Buffer pH 7.5 (Tris-HCl, 170 mM, CaCl2 4 
mM, ascorbic acid 0.01% and pargyline (10 µM; to prevent metabolism of 5-HT)).  Slides were 
then incubated at room temperature for 90 min in fresh Tris buffer containing 2 nM [
3
H]8-OH-
DPAT (Amersham, specific activity 229 Ci/mmol).  Non-specific binding was determined for 
two slides per area using 5-HT (1 µM) added to the incubation medium.  The slides were then 
washed (2 x 5 min) in ice cold Tris buffer, dipped in distilled water, and air dried.   
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Slides were secured inside an X-ray cassette and exposed to Biomax Hyperfilm
TM
 together with 
a [
3
H] microscale
TM
 calibration strip (Amersham) and left for 8-12 weeks before the film was 
developed using an automatic processor. 
 
Densitometry 
The density of [
3
H]-citalopram and [
3
H]-8-OH-DPAT binding and the relative abundance of the 
mRNAs were determined by densitometric quantification of quadruplicate sections using NIH 
Scion image software.  For bilateral structures measurements were taken from both sides and 
averaged.  Density values were calibrated to the [
3
H]- or [
14
C]-microscales, and converted to 
nCi/g tissue.  Non-specific binding for [
3
H]-citalopram (defined with fluoxetine) and for [
3
H]-8-
OH-DPAT (defined with 5-HT) was negligible and was not subtracted before analysis.   
 
Statistics 
Binding data were initially analysed by 3 way ANOVA with brain region treated as a repeated 
measure and treatment 1 (Org 34850 or vehicle) and treatment 2 (fluoxetine or vehicle) as 
between subjects factors.  Subsequently individual two-way ANOVA on each brain region was 
was used, with treatment 1 and treatment 2 as between-groups factors. Where significant 
interactions were found, post-hoc comparisons between individual treatment groups were made 
using t-test.  To account for the multiple comparisons made, Bonferroni correction was applied 
with p≤0.0045 for the [
3
H]-citalopram binding and p≤0.0038 for the [
3
H]-8-OHDPAT binding 
being considered as statistically significant.  
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In situ hybridization data were subject to two-way ANOVA and, where significant interactions 
were found, post-hoc t-test. 
 
 
RESULTS 
 
Expression of 5-HTT in the forebrain and midbrain 
Analysis of [
3
H]-citaopram binding data by three-way ANOVA revealed significant main effects 
of ‘brain region’ (F10,230=333, p<0.001) and significant ‘brain region’ x ‘treatment 1’ (F10,230=4.7, 
p<0.001) and ‘brain region’ x ‘treatment 2’ (F10,230=109, p<0.001) interactions.  There were also 
significant main effects of ‘treatment 1’ (F1,23=14,. p=0.001) and ‘treatment 2’ (F1,23=671, 
p<0.001) and a significant ‘treatment 1’ x ‘treatment 2’ interaction (F1,23=8.2, p=0.009).  Further 
2-way ANOVAs on the individual brain regions are reported below. 
Prefrontal cortex:  [
3
H]-citalopram binding was evident in a laminar distribution in the PFC 
including in the cingulate, prelimbic and infralimbic regions of the medial PFC (mPFC) (Figure 
1A).  In all regions of the mPFC, treatment with Org 34850 caused a small decrease (<15%) 
while fluoxetine treatment caused a marked reduction (approx. 60%) in [
3
H]-citalopram binding.  
When fluoxetine and Org 34850 treatments were combined, [
3
H]-citalopram binding was even 
further reduced and in some animals was close to the limit of detection (Figure 2).  Two-way 
ANOVA showed a significant effect of fluoxetine and a significant effect of Org 34850, but 
there was no significant interaction between the treatments (Table 1; Figure 3). 
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Dorsal hippocampus. In the dorsal hippocampus [
3
H]-citalopram binding was dense in Ammon’s 
horn with the highest density in stratum oriens of CA2 at the apex of the horn.  Much lower 
binding was seen in the dentate gyrus which could not be anatomically discriminated (Figure 
1B).  In Ammon’s horn treatment with Org 34850 alone caused a very small increase in 
[
3
H]-citalopram binding.  In all subregions, treatment with chronic fluoxetine alone markedly 
reduced [
3
H]-citalopram binding.  However, in animals treated with the combination of 
fluoxetine and Org 34850, [
3
H]-citalopram binding was reduced much more than in animals 
treated with fluoxetine alone (Figure 2).  Two-way ANOVAs in each subregion revealed 
significant main effect of fluoxetine in all subregions, and a significant Org 34850 x fluoxetine 
interaction in CA2 and CA3 (Table 1; Figure 3). Post-hoc t test revealed that [
3
H]-citalopram 
binding in the Org 34850/ fluoxetine group was significantly lower than in the fluoxetine alone 
group. 
 
Ventral hippocampus. In the ventral hippocampus [
3
H]-citalopram binding could clearly be seen 
in Ammon’s horn with much lower expression in dentate gyrus (not measured) (Figure 1C).  In 
the group treated with Org 34850 alone, [
3
H]-citalopram binding was slightly increased relative 
to the vehicle/vehicle group.  Treatment with fluoxetine alone decreased [
3
H]-citalopram binding 
in Ammon’s horn.  However, in the animals treated with the combination of Org 34850 and 
fluoxetine, [
3
H]-citalopram binding was reduced below the level seen after fluoxetine alone 
(Figure 2).  Two-way ANOVA revealed a significant main effect of fluoxetine and a significant 
Org 34850 x fluoxetine interaction in all subregions (Table 1; Figure 3). Post-hoc t test revealed 
that in all subregions [
3
H]-citalopram binding in the Org 34850/ fluoxetine group was 
significantly lower than in the fluoxetine alone group. 
SE Gartside 
12 
 
Midbrain: In the midbrain [
3
H]-citalopram binding was densely expressed in the raphe nuclei 
(Figure 1D).  In both the DRN and MRN, chronic Org 34850 treatment slightly reduced [
3
H]-
citalopram binding.  Chronic fluoxetine treatment caused a marked reduction in [
3
H]-citalopram 
binding in both nuclei (Figure 2). In the group treated with fluoxetine and Org 34850 combined, 
[
3
H]-citalopram binding was even more reduced.  Two-way ANOVA in the DRN and the MRN 
showed significant main effects of Org 34850 and fluoxetine but no significant interaction 
between treatments (Table 1; Figure 3).  
 
Expression of mRNAs coding for 5-HTT, TPH and 5-HT1A autoreceptor in the DRN 
The mRNAs coding for 5-HTT, TPH and the 5-HT1A autoreceptor were highly and selectively 
expressed in the raphe nuclei. Within the midbrain sections examined signal was restricted to the 
DRN and adjacent ventral MRN.  There were no significant effects of Org 34850 or fluoxetine or 
the fluoxetine/Org 34850 combination on the levels of expression of mRNAs coding for 5-HTT, 
TPH or the 5-HT1A autoreceptor in the DRN (Table 1; Figure 4).  Thus, two-way ANOVA 
showed no significant main effects and no significant interactions. 
 
Effects of Org 34850 and fluoxetine on 5-HT1A receptor protein.  
Analysis of [
3
H]-8-OHDPAT binding data by three-way ANOVA revealed a significant main 
effect of ‘brain region’ (F12,288=972, p<0.001), and a significant ‘brain region’ x ‘treatment 2’ 
interaction (F12,288=2.2, p=0.011).  However, there was no significant effect of ‘treatment 1’ 
(F1,24=0, n.s.) or ‘treatment 2’ (F1,24=0, n.s.) and no significant ‘treatment 1’ x ‘treatment 2’ 
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interaction (F1,24=1.4, n.s.).  Further 2-way ANOVAs on the individual brain regions are reported 
below. 
Prefrontal cortex: In sections containing the PFC, [
3
H]-8-OH-DPAT binding was present in the 
cortex but not the corpus callosum or anterior commissure (Figure 5A).  Within the cortex, the 
distribution was laminar being lowest in superficial layers and highest in layers V and VI.  In the 
medial PFC binding was particularly dense in layer VI adjacent to the corpus callosum.  There 
were no significant effects of Org 34850 or fluoxetine treatment on [
3
H]-8-OH-DPAT binding in 
any parts of the PFC and no interaction between treatments (Table 1; Figure 6). 
 
Dorsal hippocampus: In the dorsal hippocampus [
3
H]-8-OH-DPAT binding was dense in stratum 
oriens and stratum radiatum dendritic layers of Ammon’s horn, but was much lower in the 
pyramidal cell layer (Figure 5B).  Binding in CA2 was markedly lower than in the adjacent CA1 
and binding in CA3 was higher than in CA1.  In the dentate gyrus, [
3
H]-8-OH-DPAT binding 
was high in the molecular layer (which contains the dendrites of granule cells) but was low in the 
granule cell layer.  Neither Org 34850 nor fluoxetine treatment had any effect on [
3
H]-8-OH-
DPAT binding in any area and there was no interaction between Org 34850 and fluoxetine 
treatments (Table 1; Figure 6).  
 
Ventral hippocampus: The distribution of [
3
H]-8-OH-DPAT binding in the ventral (caudal) 
hippocampus was similar to that in the dorsal (rostral) hippocampus being lowest in CA2 and 
highest in CA3 and the molecular layer of the dentate gyrus.  A further dense area of binding was 
seen in the most ventral part of CA1 (Figure 5C).  In all subregions of the ventral hippocampus 
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[
3
H]-8-OH-DPAT binding was unaffected by Org 34850 or fluoxetine treatment, as well as by 
the combined Org 34850/fluoxetine treatment (Table 1; Figure 6). 
 
Midbrain raphe: In midbrain sections containing the anterior raphe nuclei, [
3
H]-8-OH-DPAT 
binding was present in the DRN and MRN (Figure 5D).  There were no significant effects of Org 
34850 or fluoxetine treatment on [
3
H]-8-OH-DPAT binding in the DRN or MRN and no 
interaction between the treatments (Table 1; Figure 6).   
 
 
Discussion 
 
Here we investigated the effects of chronic fluoxetine and Org 34850 treatment, alone and in 
combination, on the expression of mRNAs and proteins associated with pre- and post-synaptic 
aspects of 5-HT neurotransmission.  Chronic fluoxetine treatment caused a striking decrease in 
[
3
H]-citalopram binding (a measure of 5-HTT expression) in cortex and hippocampus, as well as 
in the raphe nuclei.  Importantly, concurrent Org 34850 and fluoxetine treatment markedly 
enhanced this decrease in 5-HTT levels, whilst Org 34850 treatment alone caused only small 
(and in some cases opposing) effects on 5-HTT.  There were no changes in the expression of 
mRNAs coding 5-HTT, TPH or the 5-HT1A receptor, suggesting these effects were not mediated 
through changes in gene transcription.  Furthermore, there were no significant effects of any of 
the treatments on either 5-HT1A autoreceptor or postsynaptic 5-HT1A receptor levels (measured 
by [
3
H]-8-OH-DPAT binding).  Org 34850 is a steroid molecule (for structure see Bachmann, et 
al 2003) which has highest affinity for the GR (pEC50=8.0) with 3-fold selectivity over 
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progesterone receptors and more than 300-fold selectivity over MR (Organon Laboratories in-
house data).  Our results indicate that the ability of GR antagonists (including Org 34850) to 
augment the effect of an SSRI on forebrain 5-HT (Johnson et al., 2007) results from a 
widespread enhancement of the fluoxetine-induced down-regulation of 5-HTT.  This 
augmentation of extracellular 5-HT appears not to cause any marked change in forebrain 5-HT1A 
receptor expression.  Given the proposed importance of 5-HT1A receptor-mediated transmission 
to the antidepressant response, these data indicate that co-administration of GR antagonists may 
effectively augment the antidepressant response to SSRI treatment. 
 
Down-regulation of the 5-HT transporter 
Chronic fluoxetine treatment induced a marked reduction in 5-HTT expression.  Several studies 
have reported that chronic administration of other SSRIs decreases the Bmax of 5-HTT binding 
(Pineyro, et al 1994; Benmansour, et al 1999; Benmansour, et al 2002; Gould, et al 2006).  
Moreover, in complete accord with the present findings, Durand et al., (Durand, et al 1999) 
demonstrated a marked decrease in [
3
H]-citalopram binding following chronic treatment with 
fluoxetine.  Whilst, other reports suggest that chronic fluoxetine fails to decrease 5-HTT levels 
(Dewar, et al 1993; Gobbi, et al 1997; Hebert, et al 2001), the low doses of fluoxetine and/or 
lengthy washout periods used may account for these discrepancies.  In the present study we 
measured 5-HTT binding in brains taken around 24 h after the last of 14 daily injections of 
fluoxetine (at the same point as we had made our measures of 5-HT levels (Johnson, et al 2007)), 
and our binding protocol included a room temperature wash step to remove any residual drug.  
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The principal finding of this study is Org 34850 treatment enhanced the down-regulation of the 
5-HTT induced by fluoxetine.  In the PFC and raphe nuclei, Org 34850 had an additive effect 
with fluoxetine reducing 5-HTT more than either treatment alone.  However, in the hippocampus 
Org 34850 alone had no effect or tended to increase 5-HTT but, when combined with fluoxetine, 
displayed a marked synergy reducing 5-HTT to very low levels.  Down-regulation of 5-HTT 
may have a very important role in the delayed emergence of the neurochemical and 
antidepressant effects of SSRIs.  Thus, Benmansour and colleagues showed that the SSRI-
induced decrease in 5-HTT has a much more marked effect on extracellular 5-HT than does the 
presence of the reuptake inhibitor itself (Benmansour, et al 2002).  Perhaps because during acute 
blockade, the dynamic competition between the reuptake inhibitor and the increasing levels of 
extracellular 5-HT limits the consequences whilst, following down-regulation of the 5-HTT (i.e. 
a loss of 5-HTT protein from the membrane) no such competition can take place.  Org 34850 in 
combination with fluoxetine lead to a greater down-regulation of 5-HTT, and so might be 
expected to lead to a greater enhancement of extracellular 5-HT levels, than fluoxetine alone. 
Thus, the biochemical data presented here are consistent with in vivo microdialysis findings in 
which we observed that concurrent treatment with Org 34850 enhanced the effect of fluoxetine 
on extracellular 5-HT in the PFC (Johnson, et al 2007).  However, it is worth noting that whilst 
the present data showed Org 34850 alone caused a small reduction in 5-HTT in the PFC, this 
treatment failed to affect extracellular 5-HT levels.  One explanation for this is that there is spare 
transporter capacity and so the modest reduction in 5-HTT induced by Org 34850 alone is of 
insufficient magnitude to elevate 5-HT levels.   
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In addition to providing a mechanistic explanation for our previous findings (Johnson, et al 
2007), the present data suggest that the augmentation of the effect of an SSRI on 5-HT would not 
be confined to the PFC (where our microdialysis was performed) but would occur widely 
through the brain.  Indeed, in both dorsal and ventral hippocampus we found evidence for a true 
synergy between fluoxetine and Org 34850, which would predict a synergistic interaction in 
respect of extracellular 5-HT levels. 
 
The fact that GRs are transcription regulatory proteins raises the possibility that the effect of the 
GR antagonist might be mediated by changes in mRNA expression.  GRs have been shown to be 
expressed in 5-HT neurones in both the DRN and MRN (Harfstrand, et al 1986), thereby having 
the potential to regulate protein synthesis within 5-HT neurones.  However, none of the 
treatments affected expression of 5-HTT mRNA in the raphe nuclei.  Whilst the effect of GR 
antagonists on 5-HTT mRNA has not been previously studied, the lack of effect of fluoxetine is 
consistent with previous data showing that chronic treatment with the same dose of fluoxetine 
did not alter 5-HTT mRNA measured at 21 days (Neumaier, et al 1996; Le Poul, et al 2000). 
 
TPH2 mRNA expression was also unaltered by any of the treatments suggesting that the 
alterations in extracellular 5-HT following fluoxetine, and its enhancement by GR antagonists 
(Johnson et al., 2007) does not arise from a transcriptional changes in the TPH2 gene.   
 
5-HT1A autoreceptors 
None of the treatments altered the mRNA coding the 5-HT1A autoreceptor in the DRN or the 
5-HT1A protein in either DRN or MRN.  We have previously found functional desensitization of 
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the somatodendritic 5-HT1A autoreceptor following chronic fluoxetine (Gartside, et al 2003; 
Johnson, et al 2007).  The present data indicate that this desensitization is not the result of a 
decrease in 5-HT1A receptor gene transcription or protein levels.  This concurs with previous 
studies reporting fluoxetine-induced desensitization in 5-HT1A autoreceptor function without 
concomitant changes in receptor binding (Le Poul, et al 1995; Hanoun, et al 2004).  
 
Postsynaptic 5-HT1A receptors  
Postsynaptic 5-HT1A receptors, in both hippocampus and PFC, have been hypothesised to play 
an important role in the antidepressant response (Cowen 2000; Celada, et al 2004).  For this 
reason we examined the effect of chronic SSRI and Org 34850 treatment on the expression of 
this receptor.  Neither Org 34850 nor fluoxetine significantly altered 8-OH-DPAT binding across 
all forebrain regions measured.  The lack of effect of fluoxetine is in line with previous reports 
that chronic administration of SSRIs fails to alter 5-HT1A receptor binding in forebrain (Li, et al 
1993; Le Poul, et al 2000; Hensler 2002).  Consistent with this, in depressed patients, post-
synaptic 5-HT1A receptor binding measured by positron emission tomography was recently 
reported to be unchanged by chronic SSRI treatment (Moses-Kolko, et al 2007).  The effects of 
chronic GR antagonist treatment on 5-HT1A binding have not been examined previously 
however, 5-HT1A binding is reportedly unchanged in GR deficient mice compared to wild types 
(Meijer, et al 1997).  Crucially, in the present study we found that the combination of fluoxetine 
and Org 34850 also failed to alter 5-HT1A receptor binding.  This suggests that the marked 
increase in extracellular 5-HT which arises from combined SSRI and GR antagonist treatment 
(Johnson, et al 2007) does not lead to changes in the number of postsynaptic 5-HT1A receptors. 
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Although 5-HT1A receptor number was not decreased the treatments, it cannot be assumed that 
5-HT1A receptor function is unaltered.  That said, much evidence suggests that chronic SSRI 
treatment does not affect postsynaptic 5-HT1A receptor sensitivity (Dong, et al 1999; Le Poul, et 
al 2000); (Li, et al 1997; Hensler 2002).  Indeed, since chronic administration of direct 5-HT1A 
receptor agonists has been shown not to alter 5-HT1A receptor sensitivity in CA3 (Dong, et al 
1997; Haddjeri, et al 1999), one can conclude that these receptors are unresponsive to agonist-
induced down-regulation or desensitization.  Thus, although the combined treatment with 
fluoxetine and Org 34850 causes a marked increase in extracellular 5-HT (Johnson, et al 2007), 
we would predict that this would not alter 5-HT1A receptor sensitivity.   
 
Conclusion 
In our previous study we found that co-treatment with GR antagonists enhanced the SSRI-
induced increase in extracellular 5-HT in the PFC (Johnson, et al 2007).  Here we show that the 
mechanism underlying this interaction is an augmentation by the GR antagonist of the 
fluoxetine-induced down-regulation of 5-HTT.  Moreover, this enhancement of transporter 
down-regulation is widespread, suggesting that GR antagonists have the potential to enhance 
SSRI effects on extracellular 5-HT in many brain areas.  We have also shown that combined GR 
antagonist/SSRI treatment does not result in a decrease in 5-HT1A receptor protein and have 
presented evidence which argues against there being a downstream functional desensitization of 
these receptors.  Thus, we predict that the overall effect of co-administration of a GR antagonist 
and an SSRI will be a marked enhancement of forebrain 5-HT1A receptor-mediated 
neurotransmission.  It has been hypothesised that an antidepressant response arises from 
increased postsynaptic 5-HT1A receptor-mediated transmission in the forebrain (Cowen 2000; 
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Celada, et al 2004).  Hence, our data indicate that co-administration of GR antagonists may 
effectively augment the antidepressant response to SSRI treatment. 
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Table 1.   
 
  Org 34850 Fluoxetine Interaction 
[
3
H]-Citalopram binding 
 
d.f  F p  F p  F p 
Prefrontal 
cortex 
Cingulate 1,28   14.3 0.001   464.8 <0.0001   0. 5 0.509 
Prelimbic 1,28   12.4 0.002   234.3 <0.0001   0.0 0.840 
Infralimbic 1,28   12.2 0.002   362.9 <0.0001   0.5 0.471 
Dorsal 
hippocampus 
CA1 1,26   2.7 0.111   216.7 <0.0001   4.8 0.038 
CA2 1,26  7.1 0.013  378.2 <0.0001    8.6 0.007 
CA3 1,26   6.4 0.018   362.6 <0.0001   10.9 0.003 
Ventral 
hippocampus 
CA1 1,26   0.7 0.398   119.8 <0.0001   10.1 0.004 
CA2 1,27   2.9 0.103   329.4 <0.0001   11.8 0.002 
CA3 1,27   0.9 0.340   208.3 <0.0001   10.5 0.003 
Midbrain DRN 1,26   19.8 <0.0001   416.0 <0.0001   0.7 0.420 
MRN 1,28  21.0 0.0001   346.1 <0.0001  0.8 0.391 
 
5-HTT mRNA 
Midbrain  DRN 1,27  1.2 0.282   0.5 0.469
  
  1.7 0.202 
     
TPH2 mRNA     
Midbrain DRN 1,25  0.4 0.539   0.0 0.979   1.4 0.243 
 
5-HT1A mRNA 
Midbrain DRN 1,26  0.2 0.643   0.5 0.469   0.0 0.899 
 
[
3
H]-8-OH-DPAT binding 
Prefrontal 
cortex 
Cingulate 1,27   0.7 0.404   2.3 0.142   0.3 0.570 
Prelimbic 1,27   4.1 0.052   0.0 0.975   3.4 0.078 
Infralimbic 1,28   1.3 0.258   0.0 0.864   2.6 0.117 
Dorsal 
hippocampus 
CA1 1,27   1.6 0.221   2.5 0.122   0.5 0.493 
CA2 1,27   0.0 0.891   1.4 0.256   3.8 0.063 
CA3 1,27   2.6 0.119   6.4 0.017   0.9 0.345 
DG 1,27   0.5 0.471   8.7 0.007   3.5 0.071 
Ventral 
hippocampus 
CA1 1,27   0.3 0.625   2.9 0.099   2.5 0.127 
CA2 1,26   0.2  0.784   0.3 0.592   4.1  0.053 
CA3 1,26   1.2 0.287   0.0 0.957   3.6 0.068 
DG 1,26   0.5 0.483   0.2 0.706   1.5 0.227 
Midbrain DRN 1,28   0.7 0.417   2.4 0.135   0.2 0.655 
MRN 1,28   0.5 0.829   2.6 0.120   0.3 0.580 
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 Table 1.  Statistical analysis.  Results of two-way ANOVA with fluoxetine and Org 34850 as 
factors.  ‘Org 34850’ refers to the main effect of Org 34850 administration, ‘Fluoxetine’ refers 
the main effect of fluoxetine administration and ‘interaction’ refers to the Org 34850 by 
fluoxetine interaction.  Degrees of freedom (d.f.), F ratio and the raw p value for each analysis 
are given.  Figures in bold type are statistically significant (p<0.0045) following Bonferroni 
correction for multiple comparisons. 
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Figure 1. Autoradiograms showing [
3
H]-citalopram binding in PFC, dorsal hippocampus, ventral 
hippocampus and midbrain raphe nuclei of vehicle/vehicle treated animals.  Regions analysed by 
densitometry are labelled:- Cg: cingulate cortex; PrL: prelimbic cortex; IL: infralimbic cortex; 
CA1-CA3: Cornus Ammon 1-3; DG: dentate gyrus; DRN: dorsal raphe nucleus; MRN: median 
raphe nucleus. 
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Figure 2.  Autoradiograms showing [
3
H]-citalopram binding in prefrontal cortex (PFC), dorsal 
hippocampus (DH), ventral hippocampus (VH) and midbrain in animals treated with 
vehicle/vehicle (Veh/Veh), Org 34850/vehicle (Org/Veh), vehicle/fluoxetine (Veh/Fluox) and 
Org 34850/fluoxetine (Org/Fluox).  The final row shows non specific binding (NSB) in each 
region.  Autoradiograms shown are from individual animals displaying [
3
H]-citalopram binding 
densities typical of each treatment group. 
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Figure 3.  Density of [
3
H]-citalopram binding in subregions of the mPFC (A), dorsal 
hippocampus (B), ventral hippocampus (C) and midbrain raphe (D) in animals treated with 
vehicle/vehicle, Org 34850/vehicle, vehicle/fluoxetine and Org 34850/fluoxetine.  Cg: cingulate 
cortex; PrL: prelimbic cortex; IL: infralimbic cortex; dCA1-3: dorsal Cornus Ammon 1-3; 
vCA1-3: ventral Cornus Ammon 1-3. Data are mean + s.e.m.. N=7 or 8 per group.  o denotes 
significant effect of Org 34850, f denotes significant main effect of fluoxetine, i denotes 
significant interaction.  See text and Table 1 for full details of statistical analysis. 
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Figure 4.  Density of expression of mRNAs for 5-HTT (A), TPH (B) and 5-HT1A receptor (C) in 
the DRN in animals treated with vehicle/vehicle, Org 34850/vehicle, vehicle/fluoxetine and Org 
34850/fluoxetine.  Data are mean + s.e.m.. N=7/8 per group.  See text and Table 1 for full details 
of statistical analysis. 
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Figure 5.  Autoradiograms showing distribution and relative densities of [
3
H]-8-OH-DPAT 
binding in prefrontal cortex, dorsal hippocampus, ventral hippocampus and midbrain raphe 
nuclei. All autoradiograms are from animals treated with vehicle/vehicle and are typical of the 
group. 
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Figure 6.  Density of [
3
H]-8-OH-DPAT binding in subregions of the PFC (A), the dorsal 
hippocampus (B), the ventral hippocampus (C), and the DRN / MRN (D) in animals treated with 
vehicle/vehicle, Org 34850/vehicle, vehicle/fluoxetine and Org 34850/fluoxetine.  Cg: cingulate 
cortex; PrL: prelimbic cortex; IL: infralimbic cortex; dCA1-3: dorsal Cornus Ammon 1-3; dDG: 
dorsal dentate gyrus; vCA1-3: ventral Cornus Ammon 1-3; vDG: ventral dentate gyrus.  Data are 
mean + s.e.m.. N=7 or 8 per group.  o denotes significant effect of Org 34850, f denotes 
significant main effect of fluoxetine, i denotes significant interaction. See text and Table 1 for 
full details of statistical analysis. 
